135 related articles for article (PubMed ID: 37625370)
1. Metronomic capecitabine with rapamycin exerts an immunosuppressive effect by inducing ferroptosis of CD4
Wang H; Yang R; Wang Z; Cao L; Kong D; Sun Q; Yoshida S; Ren J; Chen T; Duan J; Lu J; Shen Z; Zheng H
Int Immunopharmacol; 2023 Nov; 124(Pt A):110810. PubMed ID: 37625370
[TBL] [Abstract][Full Text] [Related]
2. Metronomic capecitabine inhibits liver transplant rejection in rats by triggering recipients' T cell ferroptosis.
Wang H; Wang ZL; Zhang S; Kong DJ; Yang RN; Cao L; Wang JX; Yoshida S; Song ZL; Liu T; Fan SL; Ren JS; Li JH; Shen ZY; Zheng H
World J Gastroenterol; 2023 May; 29(20):3084-3102. PubMed ID: 37346150
[TBL] [Abstract][Full Text] [Related]
3. A nanotherapeutic strategy that engages cytotoxic and immunosuppressive activities for the treatment of cancer recurrence following organ transplantation.
Yang Z; Xie H; Wan J; Wang Y; Zhang L; Zhou K; Tang H; Zhao W; Wang H; Song P; Zheng S
EBioMedicine; 2023 Jun; 92():104594. PubMed ID: 37167784
[TBL] [Abstract][Full Text] [Related]
4. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience.
Zhou J; Fan J; Wang Z; Wu ZQ; Qiu SJ; Huang XW; Yu Y; Sun J; Xiao YS; He YF; Wang YQ; Tang ZY
World J Gastroenterol; 2006 May; 12(19):3114-8. PubMed ID: 16718799
[TBL] [Abstract][Full Text] [Related]
5. The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation.
Ravaioli M; Cucchetti A; Pinna AD; De Pace V; Neri F; Barbera MA; Maroni L; Frega G; Palloni A; De Lorenzo S; Ripoli MC; Pantaleo MA; Cescon M; Del Gaudio M; Brandi G
Sci Rep; 2017 Sep; 7(1):11305. PubMed ID: 28900245
[TBL] [Abstract][Full Text] [Related]
6. Protein phosphatase 2A-B55β mediated mitochondrial p-GPX4 dephosphorylation promoted sorafenib-induced ferroptosis in hepatocellular carcinoma via regulating p53 retrograde signaling.
Qian B; Che L; Du ZB; Guo NJ; Wu XM; Yang L; Zheng ZX; Gao YL; Wang MZ; Chen XX; Xu L; Zhou ZJ; Lin YC; Lin ZN
Theranostics; 2023; 13(12):4288-4302. PubMed ID: 37554285
[No Abstract] [Full Text] [Related]
7. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.
Schnitzbauer AA; Zuelke C; Graeb C; Rochon J; Bilbao I; Burra P; de Jong KP; Duvoux C; Kneteman NM; Adam R; Bechstein WO; Becker T; Beckebaum S; Chazouillères O; Cillo U; Colledan M; Fändrich F; Gugenheim J; Hauss JP; Heise M; Hidalgo E; Jamieson N; Königsrainer A; Lamby PE; Lerut JP; Mäkisalo H; Margreiter R; Mazzaferro V; Mutzbauer I; Otto G; Pageaux GP; Pinna AD; Pirenne J; Rizell M; Rossi G; Rostaing L; Roy A; Turrion VS; Schmidt J; Troisi RI; van Hoek B; Valente U; Wolf P; Wolters H; Mirza DF; Scholz T; Steininger R; Soderdahl G; Strasser SI; Jauch KW; Neuhaus P; Schlitt HJ; Geissler EK
BMC Cancer; 2010 May; 10():190. PubMed ID: 20459775
[TBL] [Abstract][Full Text] [Related]
8. Everolimus-based immunosuppression in patients with hepatocellular carcinoma at high risk of recurrence after liver transplantation: a case series.
Ferreiro AO; Vazquez-Millán MA; López FS; Gutiérrez MG; Diaz SP; Patiño MJ
Transplant Proc; 2014 Dec; 46(10):3496-501. PubMed ID: 25498079
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies.
Matsuda Y; Ichida T; Fukumoto M
Med Mol Morphol; 2011 Sep; 44(3):117-24. PubMed ID: 21922382
[TBL] [Abstract][Full Text] [Related]
10. Acceleration of apoptosis in CD4+CD8+ thymocytes by rapamycin accompanied by increased CD4+CD25+ T cells in the periphery.
Tian L; Lu L; Yuan Z; Lamb JR; Tam PK
Transplantation; 2004 Jan; 77(2):183-9. PubMed ID: 14742978
[TBL] [Abstract][Full Text] [Related]
11. Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells.
Zhang Z; Yao Z; Wang L; Ding H; Shao J; Chen A; Zhang F; Zheng S
Autophagy; 2018; 14(12):2083-2103. PubMed ID: 30081711
[TBL] [Abstract][Full Text] [Related]
12. Rapamycin combined with allogenic immature dendritic cells selectively expands CD4+CD25+Foxp3+ regulatory T cells in rats.
Wang GY; Zhang Q; Yang Y; Chen WJ; Liu W; Jiang N; Chen GH
Hepatobiliary Pancreat Dis Int; 2012 Apr; 11(2):203-8. PubMed ID: 22484590
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive Drug-Resistant Armored T-Cell Receptor T Cells for Immune Therapy of HCC in Liver Transplant Patients.
Hafezi M; Lin M; Chia A; Chua A; Ho ZZ; Fam R; Tan D; Aw J; Pavesi A; Krishnamoorthy TL; Chow WC; Chen W; Zhang Q; Wai LE; Koh S; Tan AT; Bertoletti A
Hepatology; 2021 Jul; 74(1):200-213. PubMed ID: 33249625
[TBL] [Abstract][Full Text] [Related]
14. Sirolimus and metformin synergistically inhibit hepatocellular carcinoma cell proliferation and improve long-term survival in patients with HCC related to hepatitis B virus induced cirrhosis after liver transplantation.
Shen C; Peng C; Shen B; Zhu Z; Xu N; Li T; Xie J
Oncotarget; 2016 Sep; 7(38):62647-62656. PubMed ID: 27577068
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
Gomez-Martin C; Bustamante J; Castroagudin JF; Salcedo M; Garralda E; Testillano M; Herrero I; Matilla A; Sangro B
Liver Transpl; 2012 Jan; 18(1):45-52. PubMed ID: 21932373
[TBL] [Abstract][Full Text] [Related]
16. The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma.
Brandi G; Di Federico A; Rizzo A; De Lorenzo S; Vasuri F; Brocchi S; Golfieri R; Morelli MC; Frega G; Palloni A
Anticancer Drugs; 2022 Jan; 33(1):e781-e783. PubMed ID: 34407053
[TBL] [Abstract][Full Text] [Related]
17. Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation.
Chen K; Man K; Metselaar HJ; Janssen HL; Peppelenbosch MP; Pan Q
Liver Transpl; 2014 Mar; 20(3):261-9. PubMed ID: 24376158
[TBL] [Abstract][Full Text] [Related]
18. Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft.
Donckier V; Troisi R; Toungouz M; Colle I; Van Vlierberghe H; Jacquy C; Martiat P; Stordeur P; Zhou L; Boon N; Lambermont M; Schandené L; Van Laethem JL; Noens L; Gelin M; de Hemptinne B; Goldman M
Transpl Immunol; 2004; 13(2):139-46. PubMed ID: 15380544
[TBL] [Abstract][Full Text] [Related]
19. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review.
Cholongitas E; Mamou C; Rodríguez-Castro KI; Burra P
Transpl Int; 2014 Oct; 27(10):1039-49. PubMed ID: 24943720
[TBL] [Abstract][Full Text] [Related]
20. The Importance of the Immunosuppressive Regime on Hepatocellular Carcinoma Recurrence After Liver Transplantation.
Yilmaz S; Ince V
J Gastrointest Cancer; 2021 Dec; 52(4):1350-1355. PubMed ID: 34611833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
